GlassScriptPhysician profile
Vishal Patel
NPI 1770787749
$163,495.56
in general payments reported to CMS, 2019-2025
14 companies · $87K in 2025
The $87K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,307 · 2021: $27K · 2022: $18K · 2023: $9,809 · 2024: $7,010 · 2025: $87K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Food and Beverage: $6,810 · Travel and Lodging: $5,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,486.13 |
| Food and Beverage | $6,809.95 |
| Travel and Lodging | $5,906.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,102.21 | 2021-2025 | |
| Madrigal Pharmaceuticals | $39,362.69 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $33,916.01 | 2024-2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29,233.22 | 2019-2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $1,960.00 | 2025 | Iqirvo |
| Boston Scientific Corporation | $964.26 | 2019-2025 | Therasphere Administration Set, Wallflex Duodenal |
| Shionogi INC | $804.13 | 2019 | |
| Cook Medical LLC | $800.00 | 2019 | |
| Gilead Sciences, INC. | $714.34 | 2019-2025 | Livdelzi |
| Mallinckrodt Hospital Products INC. | $426.02 | 2021-2025 | Terlivaz |
| Ferring Pharmaceuticals INC. | $81.54 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $52.58 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $47.64 | 2024 | Sotyktu |
| Dova Pharmaceuticals | $30.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.